Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.
Many therapeutic antibodies act as antagonists to competitively block cellular signaling pathways. We describe here an approach for the therapeutic use of monoclonal antibodies based on context-dependent attenuation to reduce pathologically high activity while allowing homeostatic signaling in biologically important pathways. Such attenuation is achieved by modulating the kinetics of a ligand binding to its various receptors and regulatory proteins rather than by complete blockade of signaling pathways. The anti-interleukin-1beta (IL-1beta) antibody XOMA 052 is a potent inhibitor of IL-1beta activity that reduces the affinity of IL-1beta for its signaling receptor and co-receptor but not for its decoy and soluble inhibitory receptors. This mechanism shifts the effective dose response of the cytokine so that the potency of IL-1beta bound by XOMA 052 is 20-100-fold lower than that of IL-1beta in the absence of antibody in a variety of in vitro cell-based assays. We propose that by decreasing potency of IL-1beta while allowing binding to its clearance and inhibitory receptors, XOMA 052 treatment will attenuate IL-1beta activity in concert with endogenous regulatory mechanisms. Furthermore, the ability to bind the decoy receptor may reduce the potential for accumulation of antibody.target complexes. Regulatory antibodies like XOMA 052, which selectively modulate signaling pathways, may represent a new mechanistic class of therapeutic antibodies.
Roell
Marina K
MK
Preclinical Research Department, XOMA (US) LLC, Berkeley, CA 94710, USA. roell@xoma.com
Issafras
Hassan
H
Bauer
Robert J
RJ
Michelson
Kristen S
KS
Mendoza
Nerissa
N
Vanegas
Sandra I
SI
Gross
Lisa M
LM
Larsen
Paul D
PD
Bedinger
Daniel H
DH
Bohmann
David J
DJ
Nonet
Genevieve H
GH
Liu
Naichi
N
Lee
Steve R
SR
Handa
Masahisa
M
Kantak
Seema S
SS
Horwitz
Arnold H
AH
Hunter
John J
JJ
Owyang
Alexander M
AM
Mirza
Amer M
AM
Corbin
John A
JA
White
Mark L
ML
D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D057005:Bioengineering; D005347:Fibroblasts / Q000166:cytology / Q000502:physiology; D006367:HeLa Cells / Q000187:drug effects / Q000502:physiology; D006706:Homeostasis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007375:Interleukin-1 / Q000502:physiology; D053583:Interleukin-1beta / Q000187:drug effects / Q000502:physiology*; D007668:Kidney / Q000187:drug effects / Q000502:physiology; D007700:Kinetics; D008024:Ligands; D008156:Luciferases / Q000235:genetics; D008168:Lung / Q000166:cytology / Q000502:physiology; D016328:NF-kappa B / Q000502:physiology; D010750:Phosphoproteins / Q000187:drug effects / Q000378:metabolism; D017472:Receptors, Interleukin-1 / Q000187:drug effects / Q000502:physiology; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007375:Interleukin-1; D053583:Interleukin-1beta; D008024:Ligands; D016328:NF-kappa B; D010750:Phosphoproteins; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins; D008156:Luciferases; C547697:gevokizumab
J Immunol. 1998 Dec 15;161(12):6871-7
9862719
Endocrinology. 2010 Jun;151(6):2515-27
20332197
Immunol Rev. 2008 Apr;222:9-27
18363992
J Biol Chem. 1997 Oct 31;272(44):27730-6
9346915
J Clin Invest. 1995 Jul;96(1):38-41
7615809
Nat Clin Pract Endocrinol Metab. 2008 May;4(5):240-1
18317479
Brain Behav Immun. 2007 Mar;21(3):281-9
17275255
J Clin Invest. 2002 Sep;110(6):851-60
12235117
Nature. 1997 Mar 13;386(6621):194-200
9062194
Am J Pathol. 1995 Dec;147(6):1852-61
7495308
Acta Endocrinol (Copenh). 1988 Oct;119(2):307-11
3051828
J Immunol. 2007 Jul 15;179(2):1178-89
17617611
Diabetes. 2006 Oct;55(10):2713-22
17003335
Infect Immun. 2000 Aug;68(8):4746-51
10899881
Annu Rev Immunol. 1998;16:27-55
9597123
J Immunol. 2003 Jun 15;170(12):5999-6005
12794127
FASEB J. 1994 Dec;8(15):1314-25
8001745
Curr Opin Biotechnol. 2002 Dec;13(6):609-14
12482522
Exp Cell Res. 2001 Sep 10;269(1):109-16
11525644
Proc Natl Acad Sci U S A. 1989 May;86(9):3045-9
2470087
Int J Biochem Cell Biol. 1998 Oct;30(10):1075-9
9785472
Diabetes Care. 2008 Feb;31 Suppl 2:S161-4
18227479
Eur Cytokine Netw. 1997 Sep;8(3):265-9
9346359
Arch Physiol Biochem. 2009 Oct;115(4):240-7
19645635
Immunity. 2003 Jan;18(1):87-96
12530978
Acta Endocrinol (Copenh). 1986 Dec;113(4):551-8
3538741
J Infect Dis. 2006 May 15;193(10):1419-26
16619190
Cell Host Microbe. 2009 May 8;5(5):487-97
19454352
Curr Opin Pharmacol. 2004 Aug;4(4):378-85
15251132
Arthritis Rheum. 2005 Jul;52(7):1960-7
15986340
J Exp Med. 2009 May 11;206(5):1029-36
19364880
N Engl J Med. 2007 Apr 12;356(15):1517-26
17429083
Cytokine. 1996 Mar;8(3):206-13
8833035
Infect Immun. 2009 Feb;77(2):604-14
19075023
J Exp Med. 2005 May 2;201(9):1355-9
15867089
J Exp Med. 1996 Apr 1;183(4):1841-50
8666940